Subtopic Deep Dive
Anthracycline-Induced Cardiomyopathy Mechanisms
Research Guide
What is Anthracycline-Induced Cardiomyopathy Mechanisms?
Anthracycline-induced cardiomyopathy mechanisms encompass topoisomerase-II inhibition, mitochondrial iron accumulation, and DNA damage pathways driving doxorubicin cardiotoxicity in cardiomyocytes.
Research identifies topoisomerase-II inhibition and mitochondrial dysfunction as primary mechanisms (Minotti et al., 2004, 3655 citations). Mitochondrial iron accumulation exacerbates ROS production and myocyte apoptosis (Ichikawa et al., 2014, 859 citations). Over 10 key papers detail dose-dependent fibrosis and imaging biomarkers (Zamorano et al., 2016a, 2446 citations; Plana et al., 2014, 1745 citations).
Why It Matters
Mechanistic insights enable cardioprotective agents like dexrazoxane without reducing doxorubicin antitumor efficacy (Minotti et al., 2004). ESC guidelines recommend strain imaging for early detection, reducing heart failure incidence by 20-30% in high-risk patients (Zamorano et al., 2016a; Plana et al., 2014). Mitochondrial iron targeting identifies novel therapies, improving 5-year survival in breast cancer survivors with cardiotoxicity (Ichikawa et al., 2014; McGowan et al., 2017).
Key Research Challenges
Dose-Dependent Toxicity Prediction
Cumulative anthracycline doses above 300 mg/m² predict cardiomyopathy, but individual variability persists (Minotti et al., 2004). Animal models show inconsistent human translation due to species differences in topoisomerase isoforms (Volkova and Russell, 2012). Omics data integration remains limited for personalized risk scores.
Mitochondrial Iron Dysregulation
Doxorubicin induces labile iron pool accumulation in mitochondria, amplifying ROS without cytosolic iron rise (Ichikawa et al., 2014). Antioxidant therapies fail clinically due to poor mitochondrial targeting (McGowan et al., 2017). Mechanisms linking iron to apoptosis require single-cell resolution.
Early Biomarker Validation
Global longitudinal strain detects subclinical dysfunction before LVEF drop, but cutoff standardization lags (Plana et al., 2014; Zamorano et al., 2016b). Multimodality imaging protocols need prospective validation across cancer types (Curigliano et al., 2012). Circulating biomarkers like troponins show poor specificity.
Essential Papers
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Giorgio Minotti, Pierantonio Menna, Emanuela Salvatorelli et al. · 2004 · Pharmacological Reviews · 3.7K citations
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
José Luis Zamorano, Patrizio Lancellotti, Daniel Muñoz et al. · 2016 · European Heart Journal · 2.4K citations
peer reviewed
Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
Juan Carlos Plana, Maurizio Galderisi, Ana Barac et al. · 2014 · Journal of the American Society of Echocardiography · 1.7K citations
Shared Risk Factors in Cardiovascular Disease and Cancer
Ryan J. Koene, Anna E. Prizment, Anne Blaes et al. · 2016 · Circulation · 1.4K citations
Cardiovascular disease (CVD) and cancer are the 2 leading causes of death worldwide. Although commonly thought of as 2 separate disease entities, CVD and cancer possess various similarities and pos...
Anthracycline Chemotherapy and Cardiotoxicity
John McGowan, Robin Chung, Angshuman Maulik et al. · 2017 · Cardiovascular Drugs and Therapy · 920 citations
Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation
Yoshihiko Ichikawa, Mohsen Ghanefar, Marina Bayeva et al. · 2014 · Journal of Clinical Investigation · 859 citations
Doxorubicin is an effective anticancer drug with known cardiotoxic side effects. It has been hypothesized that doxorubicin-dependent cardiotoxicity occurs through ROS production and possibly cellul...
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines
Giuseppe Curigliano, Daniela Cardinale, Thomas Suter et al. · 2012 · Annals of Oncology · 844 citations
Reading Guide
Foundational Papers
Start with Minotti et al. (2004, 3655 citations) for comprehensive topoisomerase and pharmacologic mechanisms; follow with Ichikawa et al. (2014, 859 citations) for mitochondrial iron evidence using doxorubicin mouse models.
Recent Advances
McGowan et al. (2017, 920 citations) synthesizes apoptosis-fibrosis links; Zamorano et al. (2016a, 2446 citations) provides ESC imaging guidelines for clinical translation.
Core Methods
Topoisomerase-II inhibition assays, mitochondrial iron quantification via calcein quenching, global longitudinal strain via speckle-tracking echocardiography, troponin monitoring per ESC thresholds.
How PapersFlow Helps You Research Anthracycline-Induced Cardiomyopathy Mechanisms
Discover & Search
Research Agent uses citationGraph on Minotti et al. (2004) to map 3655 citing papers, revealing clusters on topoisomerase-IIβ cardiac isoforms; exaSearch queries 'doxorubicin mitochondrial iron cardiomyopathy' retrieves Ichikawa et al. (2014) and 50+ related studies with OpenAlex semantic ranking.
Analyze & Verify
Analysis Agent runs readPaperContent on Ichikawa et al. (2014) to extract iron flux data, then runPythonAnalysis with pandas to quantify ROS-dose curves from supplementary tables; verifyResponse (CoVe) cross-checks claims against Zamorano et al. (2016a), achieving GRADE B evidence for mitochondrial mechanisms.
Synthesize & Write
Synthesis Agent detects gaps in iron chelation trials post-2014 via contradiction flagging across Minotti (2004) and McGowan (2017); Writing Agent applies latexSyncCitations to generate review sections with 20 papers, latexCompile for PDF, and exportMermaid for topoisomerase-mitochondria pathway diagrams.
Use Cases
"Extract dose-response data from doxorubicin cardiotoxicity papers and plot apoptosis rates vs. cumulative dose."
Research Agent → searchPapers('anthracycline dose cardiomyopathy') → Analysis Agent → readPaperContent(Minotti 2004 + Ichikawa 2014) → runPythonAnalysis(pandas curve_fit, matplotlib scatterplot) → researcher gets CSV of fitted EC50 values and publication-ready figure.
"Draft LaTeX review section on anthracycline mechanisms with citations and pathway figure."
Synthesis Agent → gap detection(Minotti 2004, McGowan 2017) → Writing Agent → latexEditText(structured template) → latexSyncCitations(10 papers) → latexCompile → exportMermaid(ROS-iron diagram) → researcher gets compiled PDF with auto-cited mechanisms overview.
"Find GitHub repos analyzing omics data from anthracycline heart failure models."
Research Agent → citationGraph(Volkova 2012) → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect(scRNA-seq pipelines) → researcher gets 5 vetted repos with doxorubicin RNA-seq analysis code and usage notebooks.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers('anthracycline cardiomyopathy mechanisms'), structures Minotti (2004)-led clusters into taxonomy report with GRADE scores. DeepScan applies 7-step CoVe to validate Ichikawa (2014) iron claims against ESC guidelines (Zamorano 2016a), flagging contradictions. Theorizer generates hypotheses linking topoisomerase inhibition to iron dysregulation from cross-paper synthesis.
Frequently Asked Questions
What defines anthracycline-induced cardiomyopathy mechanisms?
Core pathways include topoisomerase-IIβ cardiac inhibition, mitochondrial iron accumulation driving ROS, and DNA damage-adducted topoisomerase complexes (Minotti et al., 2004; Ichikawa et al., 2014).
What methods study these mechanisms?
Animal models use echocardiography and histology for fibrosis; omics profile ROS and iron via mass spectrometry; human studies apply strain imaging per Plana et al. (2014) guidelines (Zamorano et al., 2016a).
What are key papers on this topic?
Minotti et al. (2004, 3655 citations) details molecular advances; Ichikawa et al. (2014, 859 citations) proves mitochondrial iron mediation; McGowan et al. (2017, 920 citations) reviews apoptosis pathways.
What open problems remain?
Translating animal iron accumulation to human biomarkers; isoform-specific topoisomerase inhibitors sparing anticancer activity; prospective validation of strain imaging cutoffs across regimens (Plana et al., 2014; Curigliano et al., 2012).
Research Chemotherapy-induced cardiotoxicity and mitigation with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Anthracycline-Induced Cardiomyopathy Mechanisms with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers